Nos tutelles

CNRS INSA de Lyon Université Lyon1

Nos partenaires

Bayer CropScience

Rechercher




Accueil > Actualités

Salle de Séminaire du BMSSI à Gerland

Mercredi 08/04/15 - 11h

Séminaire co-organisé par le MAP :
Marc Lemmonier, PDG d’antabio

Titre : Antibacterial drug discovery in the era of pan-antibiotic resistance

Résumé : Antibiotic resistance is a growing global health problem recognized as n°1 priority by the WHO. 5-10% of hospital patients in US and Europe develop a hospital-acquired (nosocomial) infection with annual > 25,000 deaths and > €30 billion additional costs to public health due to drug-resistant bacterial infections. The urgent need for innovative antibacterial discovery due to the emergence of drug resistance and pharma’s focus on late stage drug development represents an opportunity for small drug discovery firms. Antabio SAS is a young private biopharmaceutical company with presence in France and the UK, dedicated to the discovery of game-changing treatments of life-threatening and drug-resistant bacterial infections. Ongoing discovery programs at the company focus on the development of new combination and/or adjunctive antibiotic therapies, whereby small molecule compounds targeting key bacterial resistance and pathogenicity mechanisms are coadministered with antibiotics to enhance their effectiveness. These programs address areas of highest unmet need such as infections caused by multi-drug resistant Gram-negative pathogens for which there are no available treatments, e.g. metallo ß-lactamase (MBL) producer superbugs currently spreading worldwide.